Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells
Open Access
- 24 September 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 114 (13), 2667-2677
- https://doi.org/10.1182/blood-2009-02-206532
Abstract
Inhibitory-cell killer immunoglobulin-like receptors (KIR) negatively regulate natural killer (NK) cell–mediated killing of HLA class I–expressing tumors. Lack of KIR-HLA class I interactions has been associated with potent NK-mediated antitumor efficacy and increased survival in acute myeloid leukemia (AML) patients upon haploidentical stem cell transplantation from KIR-mismatched donors. To exploit this pathway pharmacologically, we generated a fully human monoclonal antibody, 1-7F9, which cross-reacts with KIR2DL1, -2, and -3 receptors, and prevents their inhibitory signaling. The 1-7F9 monoclonal antibody augmented NK cell–mediated lysis of HLA-C–expressing tumor cells, including autologous AML blasts, but did not induce killing of normal peripheral blood mononuclear cells, suggesting a therapeutic window for preferential enhancement of NK-cell cytotoxicity against malignant target cells. Administration of 1-7F9 to KIR2DL3-transgenic mice resulted in dose-dependent rejection of HLA-Cw3–positive target cells. In an immunodeficient mouse model in which inoculation of human NK cells alone was unable to protect against lethal, autologous AML, preadministration of 1-7F9 resulted in long-term survival. These data show that 1-7F9 confers specific, stable blockade of KIR, boosting NK-mediated killing of HLA-matched AML blasts in vitro and in vivo, providing a preclinical basis for initiating phase 1 clinical trials with this candidate therapeutic antibody.This publication has 47 references indexed in Scilit:
- Expression of the CD85j (leukocyte Ig‐like receptor 1, Ig‐like transcript 2) receptor for class I major histocompatibility complex molecules in idiopathic inflammatory myopathiesArthritis & Rheumatism, 2008
- Negative signaling by inhibitory receptors: the NK cell paradigmImmunological Reviews, 2008
- Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell functionEuropean Journal of Immunology, 2008
- Functions of natural killer cellsNature Immunology, 2008
- The DNA damage pathway regulates innate immune system ligands of the NKG2D receptorNature, 2005
- Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancerBlood, 2005
- NK CELL RECOGNITIONAnnual Review of Immunology, 2005
- Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic TransplantsScience, 2002
- The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions.The Journal of Experimental Medicine, 1996
- Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type.The Journal of Experimental Medicine, 1993